Personalis has returned to the financing font ahead of a planned scaling up of its operations. The Menlo Park, CA-based genome sequencing and interpretation company has reported interest from pharma companies in its cancer services, a trend that helped persuade investors to give it $33 million in a Series C round.
Having given a $60 million boost to 23andMe last week, Genentech has now turned to J. Craig Venter's Human Longevity for help sequencing and analyzing tens of thousands of genomes.
Days after unveiling a $60 million deal with Genentech, personal genomics pioneer 23andMe struck a new database-driven collaboration with Pfizer. There is even talk of a possible resolution with the FDA in 2015.
NextCODE has made a sharp exit. Just 15 months after some ex-deCode Genetics executives struck a deal with Amgen to create NextCODE, Chinese CRO WuXi PharmaTech has bought the genomic analysis startup for $65 million in cash.
Genentech has given 23andMe a major boost. The big biotech has reportedly paid $10 million upfront and agreed to $50 million in milestones to access 23andMe's database for target discovery of new drugs for Parkinson's disease.
Having started 2014 with major doubts hanging over its genomics operations, Roche closed the year with a renewed focus on the sector. The latest step in its plan was completed just before the holidays, when Roche agreed to buy Bina Technologies for its next-generation sequencing data analysis platform.
Autism Speaks has released details of the genome sequencing database it is building on Google's cloud platform. The plan is to sequence the whole genomes of 10,000 people in families affected by autism and make the resulting database freely available to researchers.
23andMe has found regulators in the United Kingdom more amenable to its personal genomics service than the U.S. FDA. The U.K. Medicines and Healthcare Products Regulatory Agency has given cautious backing to the company's spit test, which has a CE mark clearing it for sale in Europe.
Heavyweights of the United Kingdom biotech investing scene have backed Genomics, a spinout from the University of Oxford that is developing a genome data analysis platform. Genomics is working with unnamed pharmaceutical companies to apply the platform to drug development.
Genomics England has revealed part of how it plans to turn the huge amount of data generated by the 100,000 Genomes Project into insights into rare diseases and cancers. From today, British researchers who want to work with the data can apply to access the resource.